1. Metabolic Enzyme/Protease
  2. Liposome
  3. D-Lin-MC3-DMA

D-Lin-MC3-DMA 是一种可电离的阳离子脂质, 是一种有效的递送 siRNA 载体。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

D-Lin-MC3-DMA Chemical Structure

D-Lin-MC3-DMA Chemical Structure

CAS No. : 1224606-06-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1808
In-stock
5 mg ¥1280
In-stock
10 mg ¥1850
In-stock
25 mg ¥3700
In-stock
50 mg ¥5500
In-stock
100 mg ¥8500
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of D-Lin-MC3-DMA:

MCE 顾客使用本产品发表的 53 篇科研文献

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle.

体外研究
(In Vitro)

Preparation of MC3 Lipid Nanoparticles

Here we provide lipid molar ratios for LNPs in FDA-approved Patisiran (a siRNA targets the transthyretin (TTR) mRNA). The molar ratio of lipids in this formulation is D-Lin-MC3-DMA : DSPC : Cholesterol : PEG2000-C-DMG = 50 : 10 : 38.5 : 1.5[1], and RNA to lipid weight ratio is 0.05 (wt/wt).

A. Lipid Mixture Preparation

1. Dissolve lipids in ethanol and prepare 10 mg/m stock solutions. The lipid stock solutions can be stored at −20°C for later use.

Note 1: The ionizable lipid is usually a liquid. Due to the viscosity, it should always be weighed rather than relying on the autopipette volume.

Note 2: Cholesterol in solution should be kept warm (>37℃) to maintain fluidity. Transfer the cholesterol solution promptly to avoid cooling.

2. Prepare the lipid mixture solution as described. For each mL of lipid mixture add the following: 548 µL of 10mg/mL D-Lin-MC3-DMA (HY-112251), 254 µL of 10mg/mL Cholesterol (HY-N0322), 134 µL of 10mg/mL DSPC (HY-W040193), and 64 µL of PEG2000-C-DMG (HY-145411) [2]. Mix the solutions thoroµghly to achieve a clear solution. This mixture contains 10 mg of total lipid.

Note 3: The choice of lipids and ratios may be changed as desired and this will affect the LNP properties (size, polydispersity, and efficacy) and the amount of mRNA required.

B. siRNA Preparation

1. Prepare a 166.7 µg/mL siRNA solution with 100 mM pH 5 sodium acetate buffer.

Note 4: The lipid:siRNA weight ratio influences the encapsulation efficiency. Other weight ratios may be prepared as alternative formulations and should be adjusted accordingly by user.

C. Mixing

There are three commonly used methods to achieve rapid mixing of the solutions: the pipette mixing method, the vortex mixing method, and the microfluidic mixing method. All these mixing methods can be used for various applications.

It is important to note that pipette mixing method and vortex mixing method may yield more heterogeneous LNPs with lower encapsulation efficiencies and is prone to variability. Microfluidic devices enable rapid mixing in a highly controllable, reproducible manner that achieves homogeneous LNPs and high encapsulation efficiency. Within these devices, the ethanolic lipid mixture and aqueous solution are rapidly combined in individual streams. LNPs are formed as the two streams mix and are then collected into a single collection tube.

1. Pipette Mixing Method:

1.1. Pipette 3 mL of the siRNA solution and quickly add it into 1 mL of the lipid mixture solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) Pipette up and down rapidly for 20–30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

2. Vortex Mixing Method:

1.1. Vortex 3 mL of siRNA solution at a moderate speed on the vortex mixer. Then, Quickly add 1 mL of the lipid mixture solution into the vortexing solution (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.). Continue vortexing the resulting dispersion for another 20–30 seconds.

1.2. Incubate the resulting solution at room temperature for up to 15 minutes.

1.3. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

3. Microfluidic Mixing Method:

1.1 The 3 mL of siRNA buffer solution and 1 mL of the lipid mixture solution were mixed at a total flow rate of 12  mL/min (A 1:3 ratio of ethanolic lipid mixture to aqueous buffer is generally used.) in a microfluidic device.

Note 5: Parameters such as the flow rate ratio and total flow rate can be altered to fine-tune LNPs.

1.2. After mixing, the LNPs were dialyzed against PBS (pH 7.4) for 2 h, sterile filtered using 0.2 μm filters, and stored at 4°C.

Reference

1. Curr Issues Mol Biol. 2022 Oct 19;44(10):5013-5027.

2. Curr Protoc. 2023;3(9):e898.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

含有二硬脂酰磷脂酰胆碱 (DSPC) 的脂质纳米颗粒 (LNP) 和可电离的氨基脂质,例如二亚油基甲基-4-二甲基氨基丁酸酯 (DLin-MC3-DMA) 是有效的体内 siRNA 运载工具。LNP-siRNA 系统经过优化以在小鼠静脉注射后的肝细胞中实现最大基因沉默效力,其中包含摩尔比为 50/10/38.5/1.5 的 DLin-MC3-DMA (MC3)、DSPC、胆固醇和聚乙二醇 (PEG)-脂质。DLin-MC3-DMA 具有优化的 pKa 值,可显著增强效力[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

642.09

Formula

C43H79NO2

CAS 号
性状

液体

颜色

Colorless to light yellow

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
细胞实验: 

Ethanol 中的溶解度 : 125 mg/mL (194.68 mM; 超声助溶)

DMSO 中的溶解度 : 100 mg/mL (155.74 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.5574 mL 7.7871 mL 15.5741 mL
5 mM 0.3115 mL 1.5574 mL 3.1148 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    90% Saline

    Solubility: 6.25 mg/mL (9.73 mM); 悬浊液; 超声助溶

  • 方案 二

    请依序添加每种溶剂: 5% DMSO    40% PEG300    5% Tween-80    50% Saline

    Solubility: 5 mg/mL (7.79 mM); 悬浊液; 超声助溶

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.70%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO / Ethanol 1 mM 1.5574 mL 7.7871 mL 15.5741 mL 38.9354 mL
5 mM 0.3115 mL 1.5574 mL 3.1148 mL 7.7871 mL
10 mM 0.1557 mL 0.7787 mL 1.5574 mL 3.8935 mL
15 mM 0.1038 mL 0.5191 mL 1.0383 mL 2.5957 mL
20 mM 0.0779 mL 0.3894 mL 0.7787 mL 1.9468 mL
25 mM 0.0623 mL 0.3115 mL 0.6230 mL 1.5574 mL
30 mM 0.0519 mL 0.2596 mL 0.5191 mL 1.2978 mL
40 mM 0.0389 mL 0.1947 mL 0.3894 mL 0.9734 mL
50 mM 0.0311 mL 0.1557 mL 0.3115 mL 0.7787 mL
60 mM 0.0260 mL 0.1298 mL 0.2596 mL 0.6489 mL
80 mM 0.0195 mL 0.0973 mL 0.1947 mL 0.4867 mL
100 mM 0.0156 mL 0.0779 mL 0.1557 mL 0.3894 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
D-Lin-MC3-DMA
目录号:
HY-112251
需求量: